This was in spite of NAFDAC’s call for expression of interest for the COVID-19 related medicines, and efforts of the Agency to guide researchers and practitioners on how best to submit such medicines to NAFDAC for expedited review.
NAFDAC Director-General Prof Mojisola Adeyeye in a statement on Wednesday explained that the essence of passing through a thorough and strict test process of the herbal products was because of the harmful nature of some of the herbs.
READ ALSO: COVID-19: FEC cuts budget by N71.5bn
“That Africa as a continent is blessed with diverse plants and herbs that constitute a source of food and medicine is incontrovertible. But a claim of a cure for any disease must be subjected to clinical evaluation through well-controlled, randomised clinical trials following an approved clinical trial protocol.
“Many of these plants are very poisonous. However, NAFDAC as the agency with the mandate of safeguarding the health of Nigerians will continue to ensure that only medicinal products, including herbal remedies, that have proven safety data would be approved for use by the public.
“Presently, the Agency lists herbal medicines based on a historical perspective on the use of the products after carrying out toxicological and microbiological evaluations in the laboratories to ensure that they are, at the minimum, safe for human consumption. The listing status is valid for two years and is renewable,” Prof Adeyeye said.
The NAFDAC boss said the agency is committed to the advancement of herbal products, hence the decision to set up the Nigerian Herbal Medicine Product Committee (HMPC) which brings together manufacturers, academia, researchers and relevant stakeholders to bridge the gap often created between traditional medicine practitioners (possible patent holders) and drug manufacturers, whose responsibility it would be to formulate the products.
She said the aim was to translate the research into herbs into commercial products with proven safety and efficacy, promising that the agency will continue to encourage all stakeholders to present the products of their research findings and allow them to go through the internationally-recognised process of approval through pre-clinical and, where applicable, clinical trials.
She, however, reaffirmed NAFDAC’s commitment to encouraging and supporting sponsors with appropriate guidance to expedite the development of effective interventions to treat or prevent COVID-19.
READ ALSO: COVID-19: Buhari Orders Purchase Of Made In Nigeria Goods Only ……As FEC Approves N47bn To Transfer 40 Megawatts Of Power
Are you an artiste? Do you want your music to go viral and reach a large number of audience? Promote your music and Submit your story on Ujuayalogusblog.com by clicking here. For Advert Inquiries Tel/+44(0)7590363984
For More: Subscribe to Ujuayalogusblog.com
No comments:
Post a Comment